Literature DB >> 24767359

Cytomegalovirus disease after liver transplantation: a nationwide population-based study.

P-Y Liu1, S-B Cheng2, C-C Lin3, C-H Lin4, S-N Chang4, C-Y Cheng5, Z-Y Shi6, K-C Tung7, M-J Wu8.   

Abstract

BACKGROUND: Cytomegalovirus (CMV) disease is a significant complication after liver transplantation. The estimated incidence varies among studies, which have been conducted in single regional centers and with small cohorts. In this study, we investigated the occurrence of CMV disease among liver transplant recipients in a national cohort in Taiwan.
METHODS: This retrospective study used data from the Taiwan National Health Insurance Research Database. All liver transplant recipients in the catastrophic illness database from 2000 to 2009 were enrolled. Cases of CMV disease were identified from the admission database with the use of the ICD-9-CM code 078.
RESULTS: The national cohort consisted of 1,721 liver transplant recipients (1,200 men and 521 women) with a mean age of 43.9 ± 8.9 years at the time of transplantation. The mean follow-up duration was 3.6 ± 2.7 years. The mortality rate was 14.9% at 1 year and 20.5% at 5 years. During the study period, 84 patients (4.9%) were diagnosed with CMV disease. The overall prevalence of CMV disease was 14.5 per 100 person-years. The cumulative incidences of post-transplantation CMV infection at 3 months, 6 months, 1 year, 2 years, 5 years, and 10 years were 1.2%, 2.7%, 3.8%, 4.2%, 4.8%, and 4.9%, respectively. The most common CMV-related diseases were colitis, hepatitis, and pneumonia.
CONCLUSIONS: The risk of CMV disease was significantly elevated in the first 6 months after liver transplantation in the Taiwanese cohort.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24767359     DOI: 10.1016/j.transproceed.2013.12.009

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  4 in total

1.  Recipient Age and Mortality Risk after Liver Transplantation: A Population-Based Cohort Study.

Authors:  Hsiu-Pin Chen; Yung-Fong Tsai; Jr-Rung Lin; Fu-Chao Liu; Huang-Ping Yu
Journal:  PLoS One       Date:  2016-03-28       Impact factor: 3.240

2.  The Incidence and Effect of Cytomegalovirus Disease on Mortality in Transplant Recipients and General Population: Real-world Nationwide Cohort Data.

Authors:  Sang Hoon Han; Seul Gi Yoo; Kyung Do Han; Yeonju La; Da Eun Kwon; Kyoung Hwa Lee
Journal:  Int J Med Sci       Date:  2021-07-25       Impact factor: 3.738

3.  Clinical relevance of plasma virome dynamics in liver transplant recipients.

Authors:  Marijn Thijssen; Frank Tacke; Leen Beller; Ward Deboutte; Kwe Claude Yinda; Frederik Nevens; Wim Laleman; Marc Van Ranst; Mahmoud Reza Pourkarim
Journal:  EBioMedicine       Date:  2020-09-24       Impact factor: 8.143

Review 4.  Acute abdomen in the immunocompromised patient: WSES, SIS-E, WSIS, AAST, and GAIS guidelines.

Authors:  Federico Coccolini; Mario Improta; Massimo Sartelli; Kemal Rasa; Robert Sawyer; Raul Coimbra; Massimo Chiarugi; Andrey Litvin; Timothy Hardcastle; Francesco Forfori; Jean-Louis Vincent; Andreas Hecker; Richard Ten Broek; Luigi Bonavina; Mircea Chirica; Ugo Boggi; Emmanuil Pikoulis; Salomone Di Saverio; Philippe Montravers; Goran Augustin; Dario Tartaglia; Enrico Cicuttin; Camilla Cremonini; Bruno Viaggi; Belinda De Simone; Manu Malbrain; Vishal G Shelat; Paola Fugazzola; Luca Ansaloni; Arda Isik; Ines Rubio; Itani Kamal; Francesco Corradi; Antonio Tarasconi; Stefano Gitto; Mauro Podda; Anastasia Pikoulis; Ari Leppaniemi; Marco Ceresoli; Oreste Romeo; Ernest E Moore; Zaza Demetrashvili; Walter L Biffl; Imitiaz Wani; Matti Tolonen; Therese Duane; Sameer Dhingra; Nicola DeAngelis; Edward Tan; Fikri Abu-Zidan; Carlos Ordonez; Yunfeng Cui; Francesco Labricciosa; Gennaro Perrone; Francesco Di Marzo; Andrew Peitzman; Boris Sakakushev; Michael Sugrue; Marja Boermeester; Ramiro Manzano Nunez; Carlos Augusto Gomes; Miklosh Bala; Yoram Kluger; Fausto Catena
Journal:  World J Emerg Surg       Date:  2021-08-09       Impact factor: 5.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.